PGIM India Healthcare Fund
- NAV as on 25 Sep 2026
- ₹12.17-0.33%1 day
- Return since launch
- 11.7%
- 52-week range
- ₹9.23 — ₹12.37
- AUM
- ₹125 Cr
PGIM India Healthcare Fund is a Sectoral-Pharma equity fund from PGIM India Mutual Fund with ₹125 Cr under management, launched in 2024. The expense ratio is 2.58% and the SEBI riskometer reading is Very High.
Performance
PGIM India Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +27.0% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 35.1% | +14.2 pts | 20.9% | 26.4% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | -0.5% | −0.7 pts | 0.2% | -0.3% |
| 3M | 8.0% | +1.8 pts | 6.2% | 6.0% |
| 6M | 25.9% | +3.7 pts | 22.1% | 20.9% |
| 1Y | 27.0% | +6.2 pts | 20.9% | 19.5% |
Since launch (19 Nov 2024): 11.7%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -2.7% | −0.6 pts | -2.0% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.61%
Expense ratio as on 25 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.10%
- Brokerage
- 0.05%
- Transaction charges
- 0.00%
- Statutory levies
- 0.46%
- Exit load
- Exit load of 0.50%, if redeemed within 90 days.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
PGIM India Healthcare Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity94.6%
- Debt5.8%
Market cap split
- Large34.6%
- Mid34.2%
- Small31.3%
- P/E
- 54.65
- P/B
- 8.01
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Divi's Laboratories Ltd. | Healthcare | 10.85% | ₹13.57 Cr | +10.01% | +10.34% | +8.84% |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.74% | ₹13.43 Cr | +11.34% | +11.69% | +12.28% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 8.86% | ₹11.09 Cr | +2.66% | +3.17% | +5.11% |
| Others | Others | 5.42% | ₹6.80 Cr | +3.82% | +4.48% | +3.36% |
| Max Healthcare Institute Ltd. | Healthcare | 4.96% | ₹6.21 Cr | +4.97% | +5.81% | +7.48% |
| Ajanta Pharma Ltd. | Healthcare | 4.83% | ₹6.04 Cr | +4.68% | +4.94% | +3.29% |
| Manipal Health Enterprises Ltd. | Healthcare | 4.12% | ₹5.16 Cr | — | — | — |
| Mankind Pharma Ltd. | Healthcare | 4.07% | ₹5.09 Cr | +5.24% | +5.01% | +5.17% |
| Rubicon Research Ltd. | Healthcare | 4.01% | ₹5.02 Cr | +5.97% | +5.29% | — |
| Dr. Lal Pathlabs Ltd. | Healthcare | 3.93% | ₹4.92 Cr | +3.27% | +2.83% | +2.91% |
| Neuland Laboratories Ltd. | Healthcare | 3.26% | ₹4.08 Cr | +3.17% | +2.18% | +2.12% |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 3.15% | ₹3.95 Cr | +4.15% | +4.35% | +3.95% |
| Navin Fluorine International Ltd. | Chemicals | 3.04% | ₹3.81 Cr | +3.10% | +2.81% | +2.28% |
| Aster DM Quality Care Ltd. | Healthcare | 2.89% | ₹3.62 Cr | +6.44% | +7.07% | +5.70% |
| Abbott India Ltd. | Healthcare | 2.83% | ₹3.54 Cr | +2.92% | +3.18% | +3.48% |
| Sai Life Sciences Ltd. | Healthcare | 2.54% | ₹3.18 Cr | +2.64% | +2.98% | +2.05% |
| Cipla Ltd. | Healthcare | 2.23% | ₹2.79 Cr | +1.63% | +1.62% | +2.67% |
| Pfizer Ltd. | Healthcare | 2.12% | ₹2.65 Cr | +1.32% | — | — |
| Anthem Biosciences Ltd. | Healthcare | 1.96% | ₹2.45 Cr | +2.19% | +2.08% | +1.33% |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 1.77% | ₹2.22 Cr | +2.08% | +2.12% | +2.43% |
| Global Health Ltd. | Healthcare | 1.72% | ₹2.15 Cr | +1.81% | +1.95% | +3.39% |
| Zydus Lifesciences Ltd. | Healthcare | 1.51% | ₹1.89 Cr | — | — | +1.08% |
| Lupin Ltd. | Healthcare | 1.42% | ₹1.78 Cr | +1.35% | — | — |
| ICICI Lombard General Insurance Company Ltd. | Insurance | 1.40% | ₹1.75 Cr | +1.15% | +1.26% | +2.40% |
| Dr Agarwals Eye Hospital Ltd. | Healthcare | 1.20% | ₹1.50 Cr | +0.52% | +0.49% | +0.49% |
| Fortis Healthcare Ltd. | Healthcare | 1.10% | ₹1.37 Cr | +1.47% | — | — |
| Dr. Agarwal's Health Care Ltd. | Healthcare | 0.86% | ₹1.07 Cr | +1.06% | +0.46% | +0.48% |
| Orchid Pharma Ltd. | Healthcare | 0.80% | ₹1.00 Cr | +0.85% | +0.69% | +0.81% |
| company:16324 | Healthcare | 0.73% | ₹0.92 Cr | — | — | — |
| Lenskart Solutions Ltd. | Consumer Discretionary | 0.71% | ₹0.89 Cr | +0.74% | +0.78% | — |
| company:1748 | Healthcare | 0.51% | ₹0.63 Cr | — | — | +2.07% |
| Sagility Ltd. | Services | 0.46% | ₹0.58 Cr | +0.53% | +0.66% | +1.79% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Aster DM Quality Care Ltd. | 6.21% | 2.89% | -3.32% |
| Manipal Health Enterprises Ltd. | 0.96% | 4.12% | +3.16% |
| Others | 4.32% | 5.76% | +1.44% |
| Max Healthcare Institute Ltd. | 5.86% | 4.96% | -0.90% |
| Dr Agarwals Eye Hospital Ltd. | 0.45% | 1.20% | +0.75% |
| company:16324 | 0.00% | 0.73% | +0.73% |
| Krishna Institute of Medical Sciences Ltd | 3.77% | 3.15% | -0.62% |
| Mankind Pharma Ltd. | 4.66% | 4.07% | -0.59% |
| Torrent Pharmaceuticals Ltd. | 9.38% | 8.86% | -0.52% |
| company:1748 | 0.00% | 0.51% | +0.51% |
| ICICI Lombard General Insurance Company Ltd. | 0.89% | 1.40% | +0.51% |
| Divi's Laboratories Ltd. | 10.35% | 10.85% | +0.50% |
| Jupiter Life Line Hospitals Ltd. | 2.23% | 1.77% | -0.46% |
| Abbott India Ltd. | 3.23% | 2.83% | -0.40% |
| Ajanta Pharma Ltd. | 5.20% | 4.83% | -0.37% |
| Rubicon Research Ltd. | 3.68% | 4.01% | +0.33% |
| Navin Fluorine International Ltd. | 2.81% | 3.04% | +0.23% |
| Neuland Laboratories Ltd. | 3.03% | 3.26% | +0.23% |
| Lupin Ltd. | 1.23% | 1.42% | +0.19% |
| Fortis Healthcare Ltd. | 1.28% | 1.10% | -0.18% |
| Cipla Ltd. | 2.39% | 2.23% | -0.16% |
| Zydus Lifesciences Ltd. | 1.35% | 1.51% | +0.16% |
| Pfizer Ltd. | 2.25% | 2.12% | -0.13% |
| Dr. Lal Pathlabs Ltd. | 4.05% | 3.93% | -0.12% |
| Sun Pharmaceutical Industries Ltd. | 10.86% | 10.74% | -0.12% |
| Global Health Ltd. | 1.83% | 1.72% | -0.11% |
| Orchid Pharma Ltd. | 0.91% | 0.80% | -0.11% |
| Dr. Agarwal's Health Care Ltd. | 0.90% | 0.86% | -0.04% |
| Anthem Biosciences Ltd. | 1.99% | 1.96% | -0.03% |
| Lenskart Solutions Ltd. | 0.68% | 0.71% | +0.03% |
| Sai Life Sciences Ltd. | 2.56% | 2.54% | -0.02% |
| Sagility Ltd. | 0.48% | 0.46% | -0.02% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Fund managers
- Anandha Padmanabhan AnjeneyanMr. Anjeneyan is a B. Com, ACA, CFA, FRMPrior to joining PGIM India Asset Management Pvt Ltd, he has worked with Renaissance Investment Managers Private Limited, Canara Robeco Asset Management Company Limited.
- Puneet PalMr. Pal is a B.Com (H) and MBA from SIBM Pune.Prior to joining PGIM India Mutual Fund, he has worked with BNP Paribas AMC as Head Fixed Income, UTI AMC as Sr. Vice President & Fund Manager & TATA AMC as Fund Manager.
- Utsav MehtaMr. Mehta has done B.Com and CFAPrior to joining PGIM Mutual Fund, he has worked with Edelweiss Asset Management Ltd and Ambit Capital
- Vivek SharmaMr. Sharma is a PGDM FinancePrior to joining PGIM India Asset Management Pvt. Ltd. - Equity Analyst and Asst. Fund Manager, he has worked with ICICI Securities Ltd. - Equity Analyst and JP Morgan Services India Pvt. Ltd.- Associate - Investment Banking.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months25.85% absolute | ₹60,000 | ₹75,510 | 25.85% | |
| 1 year27.03% annualised | ₹1,20,000 | ₹1,39,106 | 15.92% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.